scholarly journals Samarium-153 Therapy and Radiation Dose for Prostate Cancer

10.5772/64670 ◽  
2016 ◽  
Author(s):  
Yasemin Parlak ◽  
Gul Gumuser ◽  
Elvan Sayit
Keyword(s):  
Prostate Cancer ◽  
Radiation Dose

Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis

2002 ◽  
Vol 53 (5) ◽  
pp. 1106-1110 ◽  
Author(s):  
Mark D Hurwitz ◽  
Lindsey Schnieder ◽  
Judith Manola ◽  
Clair J Beard ◽  
Irving D Kaplan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Dose ◽  
Retrospective Analysis ◽  
Dose Response ◽  
Low Risk ◽  
Localized Prostate Cancer

Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials

2000 ◽  
Vol 18 (14) ◽  
pp. 2740-2746 ◽  
Author(s):  
Richard Valicenti ◽  
Jiandong Lu ◽  
Miljenko Pilepich ◽  
Sucha Asbell ◽  
David Grignon
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Radiation Dose ◽  
Radiation Therapy Oncology Group ◽  
Localized Prostate Cancer ◽  
Disease Specific Survival ◽  
Oncology Group ◽  
Dose Radiation ◽  
Disease Specific

PURPOSE: We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer. METHODS: From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification system. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy). The median follow-up time was 8 years. RESULTS: A Cox regression model revealed that Gleason score was an independent predictor of disease-specific survival and overall survival. The 10-year disease-specific survival rates by Gleason score were as follows: score of 2 through 5, 85%; score of 6, 79%; score of 7, 62%; and score of 8 through 10, 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a significant predictor for improved disease-specific survival and overall survival only for those patients whose cancers had Gleason scores of 8 through 10 (P < .05). After adjusting for clinical T stage, nodal status, and age, treating with a higher radiation dose was associated with a 29% lower relative risk of death from prostate cancer and 27% reduced mortality rate (P < .05). CONCLUSION: These data demonstrate that higher-dose radiation therapy can significantly reduce the risk of dying from prostate cancer in men with clinically localized disease. This survival benefit is restricted to men with poorly differentiated cancers.

Impact of radiation dose on recurrence in high‐risk prostate cancer patients

The Prostate ◽  
2020 ◽  
Vol 80 (15) ◽  
pp. 1322-1327
Author(s):  
Matthew Deek ◽  
Wolfgang Lilleby ◽  
Victoria Vaage ◽  
Knut H. Hole ◽  
Theodore DeWeese ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radiation Dose ◽  
Cancer Patients ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer

2006 ◽  
Vol 45 (4) ◽  
pp. 454-462 ◽  
Author(s):  
Ása Karlsdottir ◽  
Ludvig Paul Muren ◽  
Tore Wentzel-Larsen ◽  
Dag C. Johannessen ◽  
August Bakke ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Dose ◽  
Hormone Therapy ◽  
Dose Escalation
Sign in / Sign up

Export Citation Format

Share Document